SCHEMBL2901914

SCHEMBL2901914

CCCCC1CCC(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.61
HTT P42858 2/20 0.53
MAPK1 P28482 2/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
PKM P14618 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NOS1 P29475 2/20 0.34
NOS2 P35228 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10881985 1.00 CYP1A2 (0.61) CYP1A2HTTMAPK1LMNAMAPT
Ammonia Solution, Strong SCHEMBL689616 0.97 CYP1A2 (0.58) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10485824 0.93 CYP1A2 (0.54) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10701936 0.93 CYP1A2 (0.54) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL8219465 0.93 CYP1A2 (0.54) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10485828 0.93 CYP1A2 (0.54) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10974028 0.92 CYP1A2 (0.52) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL3293288 0.92 CYP1A2 (0.52) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL10772877 0.90 CYP1A2 (0.50) CYP1A2HTTMAPK1LMNAMAPT
SCHEMBL19125970 0.90 CYP1A2 (0.50) CYP1A2HTTMAPK1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4347597-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS Otsuka Pharmaceutical Co., Ltd. (JP) 2024-04-10 EP claimed
CN-117377674-A Pyrazolo [1,5-a ] pyrimidine compounds for the treatment of dermatological disorders 大塚制药株式会社 2024-01-09 CN claimed
WO-2022255408-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-12-08 WO claimed
EP-0791025-B1 AQUEOUS TWO-COMPONENT POLYURETHANE COATING AGENT, METHOD FOR PREPARING IT AND ITS USE IN MULTICOAT PAINTING PROCESSES BASF COATINGS AG (DE) 2001-12-19 EP claimed
EP-4347597-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS Otsuka Pharmaceutical Co., Ltd. (JP) 2024-04-10 EP disclosed
CN-117377674-A Pyrazolo [1,5-a ] pyrimidine compounds for the treatment of dermatological disorders 大塚制药株式会社 2024-01-09 CN disclosed
EP-4219473-A1 CRYSTAL TYPE II OF MALANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME Lg Chem, Ltd. (KR) 2023-08-02 EP disclosed
US-20230190940-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-06-22 US disclosed
WO-2022255408-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-12-08 WO disclosed
EP-2154970-B1 DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES RESPIRERX PHARMACEUTICALS INC (US) 2017-10-25 EP disclosed
US-20170101659-A1 METHODS FOR INCREASING MOLECULAR DIVERSITY OF POLYKETIDES AND NON-RIBOSOMAL PROTEINS Isomerase Therapeutics Ltd. (GB) 2017-04-13 US disclosed
CN-104995255-A Curable composition and color filter FUJIFILM CORP 2015-10-21 CN disclosed
EP-1184396-A1 (Meth)acrylate ester-based resin composition Nippon Shokubai Co., Ltd. (JP) 2002-03-06 EP disclosed
US-5582774-A PHTHALOCYANINE DERIVATIVE MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1996-12-10 US disclosed
US-5446141-A Optical recording media, filters, liquid crystals display MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1995-08-29 US disclosed
EP-0337209-B1 ALKYLPHTHALOCYANINE NEAR-INFRARED ABSORBERS AND RECORDING/DISPLAY MATERIALS USING THE SAME MITSUI TOATSU CHEMICALS, Inc. (JP) 1993-08-04 EP disclosed
EP-0290391-B1 POLYOLEFINES STABILIZED AGAINST LIGHT DEGRADATION CIBA-GEIGY AG (CH) 1992-06-10 EP disclosed
US-5024926-A Heat, light, weather resistance; for optical recording media, filters, liquid crystal displays MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1991-06-18 US disclosed
EP-0337209-A2 Alkylphthalocyanine near-infrared absorbers and recording/display materials using the same MITSUI TOATSU CHEMICALS, Inc. (JP) 1989-10-18 EP disclosed
EP-0290391-A2 Polyolefines stabilized against light degradation CIBA-GEIGY AG (CH) 1988-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190940-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP1A2 3570/4885HTT 2464/4885MAPK1 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.